GenomOncology

Executive Summary

GenomOncology is a private, US-based company that provides a software platform and services for genomic data analysis to support precision oncology. Founded in 2012 and headquartered in Cleveland, Ohio, the company's platform integrates complex molecular and clinical data to generate actionable reports for clinicians, molecular pathologists, and researchers. By accelerating clinical decision-making and optimizing clinical trial matching, GenomOncology aims to improve patient care in oncology. The company operates in the rapidly growing precision medicine market, which is driven by advancements in genomic sequencing and the increasing adoption of targeted therapies. While GenomOncology has established itself as a niche player in the oncology informatics space, it faces competition from larger players like Foundation Medicine and Tempus. The company's ability to differentiate through its proprietary data integration technology and focus on clinical workflow integration will be key to its growth. As a private company, GenomOncology's financials and valuation are not publicly disclosed, but its steady presence in the biopharma ecosystem suggests ongoing partnerships and product development.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance or CE Mark for Clinical Decision Support Module60% success
• Q2 2026Strategic Partnership with a Major Cancer Center or Hospital Network70% success
• Q4 2026Launch of AI-Driven Patient Stratification Tool50% success